{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:12:42Z","timestamp":1783901562661,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the clinical research foundation of the National Clinical Research Center for Geriatric Diseases","award":["2023LNJJ13"],"award-info":[{"award-number":["2023LNJJ13"]}]},{"name":"the clinical research foundation of the National Clinical Research Center for Geriatric Diseases","award":["2022LNJJ13"],"award-info":[{"award-number":["2022LNJJ13"]}]},{"name":"Major Scientific Research Project for High-level Health Talents in Hunan Province","award":["20230462"],"award-info":[{"award-number":["20230462"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272907, 81974397"],"award-info":[{"award-number":["82272907, 81974397"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Outstanding Youth Fund Project of Hunan Province","award":["2024JJ2090"],"award-info":[{"award-number":["2024JJ2090"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01398-x","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:37:36Z","timestamp":1778074656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic biomarkers and Hedgehog pathway activation in early prostate cancer neuroendocrine differentiation via spatial profiling"],"prefix":"10.1038","volume":"10","author":[{"given":"Wenhao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1398_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1398_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","volume":"86","author":"S Liu","year":"2022","unstructured":"Liu, S., Alabi, B. R., Yin, Q. & Stoyanova, T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin. Cancer Biol. 86, 57\u201368 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1398_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies, A. H., Beltran, H. & Zoubeidi, A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15, 271\u2013286 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1398_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1398_CR5","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492\u20132503 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1398_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca, V. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer 121, 7\u201318 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1398_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein, J. I. et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756\u2013767 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"1398_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4341","volume":"23","author":"DS Rickman","year":"2017","unstructured":"Rickman, D. S., Beltran, H., Demichelis, F. & Rubin, M. A. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 23, 1\u201310 (2017).","journal-title":"Nat. Med."},{"key":"1398_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","volume":"82","author":"DG Tang","year":"2022","unstructured":"Tang, D. G. Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin. Cancer Biol. 82, 68\u201393 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1398_CR10","first-page":"0005","volume":"1","author":"A Jamroze","year":"2024","unstructured":"Jamroze, A., Liu, X. & Tang, D. G. Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance. Cancer Heterog. Plast. 1, 0005 (2024).","journal-title":"Cancer Heterog. Plast."},{"key":"1398_CR11","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","volume":"32","author":"HT Wang","year":"2014","unstructured":"Wang, H. T. et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J. Clin. Oncol. 32, 3383\u20133390 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1398_CR12","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque, M. P. et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 129, 4492\u20134505 (2019).","journal-title":"J. Clin. Invest."},{"key":"1398_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","volume":"81","author":"Q Cheng","year":"2022","unstructured":"Cheng, Q. et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur. Urol. 81, 446\u2013455 (2022).","journal-title":"Eur. Urol."},{"key":"1398_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7150\/thno.92336","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression. Theranostics 14, 1065\u20131080 (2024).","journal-title":"Theranostics"},{"key":"1398_CR15","doi-asserted-by":"publisher","unstructured":"Chen, C.-C. et al. Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2023.10.009 (2023).","DOI":"10.1016\/j.ccell.2023.10.009"},{"key":"1398_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt, C. R. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat. Biotechnol. 38, 586\u2013599 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1398_CR17","doi-asserted-by":"crossref","unstructured":"Yamada, Y. & Beltran, H. Clinical and biological features of neuroendocrine prostate cancer. Curr. Oncol. Rep. 23, 15 (2021).","DOI":"10.1007\/s11912-020-01003-9"},{"key":"1398_CR18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","volume":"5","author":"R Romero","year":"2024","unstructured":"Romero, R. et al. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nat. Cancer 5, 1641\u20131659 (2024).","journal-title":"Nat. Cancer"},{"key":"1398_CR19","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrg887","volume":"3","author":"E Li","year":"2002","unstructured":"Li, E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3, 662\u2013673 (2002).","journal-title":"Nat. Rev. Genet."},{"key":"1398_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32701-6","volume":"13","author":"TC Westbrook","year":"2022","unstructured":"Westbrook, T. C. et al. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat. Commun. 13, 5345 (2022).","journal-title":"Nat. Commun."},{"key":"1398_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41392-020-00313-5","volume":"5","author":"S Qin","year":"2020","unstructured":"Qin, S. et al. Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct. Target Ther. 5, 228 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"1398_CR22","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1398_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168649","volume":"134","author":"D Han","year":"2024","unstructured":"Han, D. et al. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. J. Clin. Invest. 134, e168649 (2024).","journal-title":"J. Clin. Invest."},{"key":"1398_CR24","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916\u20136924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1398_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s44321-024-00186-z","volume":"17","author":"J Wei","year":"2025","unstructured":"Wei, J. et al. PlexinD1 is a driver and a therapeutic target in advanced prostate cancer. EMBO Mol. Med. 17, 336\u2013364 (2025).","journal-title":"EMBO Mol. Med."},{"key":"1398_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1210\/er.2010-0027","volume":"32","author":"A Bartolomucci","year":"2011","unstructured":"Bartolomucci, A. et al. The extended granin family: structure, function, and biomedical implications. Endocr. Rev. 32, 755\u2013797 (2011).","journal-title":"Endocr. Rev."},{"key":"1398_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1749-6632.2002.tb04429.x","volume":"971","author":"SK Mahata","year":"2002","unstructured":"Mahata, S. K., Mahapatra, N. R., Mahata, M. & O\u2019Connor, D. T. Neuroendocrine cell type-specific and inducible expression of chromogranin\/secretogranin genes: crucial promoter motifs. Ann. N. Y. Acad. Sci. 971, 27\u201338 (2002).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1398_CR28","doi-asserted-by":"publisher","first-page":"jcs252916","DOI":"10.1242\/jcs.252916","volume":"134","author":"T Kundu","year":"2021","unstructured":"Kundu, T., Dutta, P., Nagar, D., Maiti, S. & Ghose, A. Coupling of dynamic microtubules to F-actin by Fmn2 regulates chemotaxis of neuronal growth cones. J. Cell Sci. 134, jcs252916 (2021).","journal-title":"J. Cell Sci."},{"key":"1398_CR29","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.neuron.2015.08.027","volume":"87","author":"C Acuna","year":"2015","unstructured":"Acuna, C., Liu, X., Gonzalez, A. & S\u00fcdhof, T. C. RIM-BPs mediate tight coupling of action potentials to Ca(2+)-triggered neurotransmitter release. Neuron 87, 1234\u20131247 (2015).","journal-title":"Neuron"},{"key":"1398_CR30","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1523\/JNEUROSCI.1875-16.2017","volume":"37","author":"S Schilling","year":"2017","unstructured":"Schilling, S. et al. APLP1 is a synaptic cell adhesion molecule, supporting maintenance of dendritic spines and basal synaptic transmission. J. Neurosci. 37, 5345\u20135365 (2017).","journal-title":"J. Neurosci."},{"key":"1398_CR31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s12035-018-1167-9","volume":"56","author":"R Coronel","year":"2019","unstructured":"Coronel, R. et al. Neuronal and glial differentiation of human neural stem cells is regulated by amyloid precursor protein (APP) levels. Mol. Neurobiol. 56, 1248\u20131261 (2019).","journal-title":"Mol. Neurobiol."},{"key":"1398_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-595","volume":"15","author":"M Kidd","year":"2014","unstructured":"Kidd, M., Modlin, I. M. & Drozdov, I. Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics 15, 595 (2014).","journal-title":"BMC Genomics"},{"key":"1398_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jnc.12051","volume":"124","author":"AJ Billnitzer","year":"2013","unstructured":"Billnitzer, A. J., Barskaya, I., Yin, C. & Perez, R. G. APP independent and dependent effects on neurite outgrowth are modulated by the receptor associated protein (RAP). J. Neurochem. 124, 123\u2013132 (2013).","journal-title":"J. Neurochem."},{"key":"1398_CR34","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1398_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305 (2016).","journal-title":"Nat. Med."},{"key":"1398_CR36","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","volume":"12","author":"S Akamatsu","year":"2015","unstructured":"Akamatsu, S. et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 12, 922\u2013936 (2015).","journal-title":"Cell Rep."},{"key":"1398_CR37","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1158\/1078-0432.CCR-21-4289","volume":"28","author":"IM Coleman","year":"2022","unstructured":"Coleman, I. M. et al. Therapeutic implications for intrinsic phenotype classification of metastatic castration-resistant prostate cancer. Clin. Cancer Res. 28, 3127\u20133140 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1398_CR38","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3389","volume":"19","author":"D Amakye","year":"2013","unstructured":"Amakye, D., Jagani, Z. & Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19, 1410\u20131422 (2013).","journal-title":"Nat. Med."},{"key":"1398_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.phrs.2019.02.027","volume":"142","author":"S Chatterjee","year":"2019","unstructured":"Chatterjee, S. & Sil, P. C. Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy. Pharm. Res. 142, 251\u2013261 (2019).","journal-title":"Pharm. Res."},{"key":"1398_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.710","volume":"5","author":"TC Dakal","year":"2024","unstructured":"Dakal, T. C. et al. Intricate relationship between cancer stemness, metastasis, and drug resistance. MedComm 5, e710 (2024).","journal-title":"MedComm"},{"key":"1398_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54709-w","volume":"15","author":"I Kats","year":"2024","unstructured":"Kats, I. et al. Spatio-temporal transcriptomics of chromothriptic SHH-medulloblastoma identifies multiple genetic clones that resist treatment and drive relapse. Nat. Commun. 15, 10370 (2024).","journal-title":"Nat. Commun."},{"key":"1398_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adi5174","volume":"18","author":"Q Zhang","year":"2025","unstructured":"Zhang, Q. et al. The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. Sci. Signal 18, eadi5174 (2025).","journal-title":"Sci. Signal"},{"key":"1398_CR43","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1158\/1078-0432.CCR-22-3736","volume":"29","author":"N Menssouri","year":"2023","unstructured":"Menssouri, N. et al. Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen receptor pathway inhibitors. Clin. Cancer Res. 29, 4504\u20134517 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1398_CR44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/pros.24122","volume":"81","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Smoothened loss is a characteristic of neuroendocrine prostate cancer. Prostate 81, 508\u2013520 (2021).","journal-title":"Prostate"},{"key":"1398_CR45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Molecular events in neuroendocrine prostate cancer development. Nat. Rev. Urol. 18, 581\u2013596 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"1398_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.955669","volume":"10","author":"H Zhou","year":"2022","unstructured":"Zhou, H. et al. Focus on the tumor microenvironment: a seedbed for neuroendocrine prostate cancer. Front. Cell Dev. Biol. 10, 955669 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1398_CR47","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24803.1","volume":"9","author":"S Shen","year":"2020","unstructured":"Shen, S. & Clairambault, J. Cell plasticity in cancer cell populations. F1000Res 9, F1000 Faculty Rev-635 (2020).","journal-title":"F1000Res"},{"key":"1398_CR48","doi-asserted-by":"publisher","first-page":"9035","DOI":"10.3892\/mmr.2017.7747","volume":"16","author":"Y Guo","year":"2017","unstructured":"Guo, Y. et al. IL\u20118 promotes proliferation and inhibition of apoptosis via STAT3\/AKT\/NF\u2011\u03baB pathway in prostate cancer. Mol. Med. Rep. 16, 9035\u20139042 (2017).","journal-title":"Mol. Med. Rep."},{"key":"1398_CR49","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ejca.2012.05.028","volume":"49","author":"J Alonzeau","year":"2013","unstructured":"Alonzeau, J. et al. The neuropeptide 26RFa is expressed in human prostate cancer and stimulates the neuroendocrine differentiation and the migration of androgeno-independent prostate cancer cells. Eur. J. Cancer 49, 511\u2013519 (2013).","journal-title":"Eur. J. Cancer"},{"key":"1398_CR50","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1038\/s41388-019-0750-5","volume":"38","author":"S Zhu","year":"2019","unstructured":"Zhu, S. et al. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. Oncogene 38, 4875\u20134884 (2019).","journal-title":"Oncogene"},{"key":"1398_CR51","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","volume":"3","author":"B Dong","year":"2020","unstructured":"Dong, B. et al. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. Commun. Biol. 3, 778 (2020).","journal-title":"Commun. Biol."},{"key":"1398_CR52","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.3390\/ijms24108955","volume":"24","author":"R Watanabe","year":"2023","unstructured":"Watanabe, R. et al. Spatial gene expression analysis reveals characteristic gene expression patterns of de novo neuroendocrine prostate cancer coexisting with androgen receptor pathway prostate cancer. Int. J. Mol. Sci. 24, 8955 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1398_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26840-5","volume":"12","author":"M Bolis","year":"2021","unstructured":"Bolis, M. et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat. Commun. 12, 7033 (2021).","journal-title":"Nat. Commun."},{"key":"1398_CR54","doi-asserted-by":"publisher","first-page":"bbac558","DOI":"10.1093\/bib\/bbac558","volume":"24","author":"C-J Liu","year":"2023","unstructured":"Liu, C.-J. et al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief. Bioinform 24, bbac558 (2023).","journal-title":"Brief. Bioinform"},{"key":"1398_CR55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166248","volume":"133","author":"G Gritsina","year":"2023","unstructured":"Gritsina, G. et al. Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth. J. Clin. Invest. 133, e166248 (2023).","journal-title":"J. Clin. Invest."},{"key":"1398_CR56","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/0008-5472.CAN-25-0587","volume":"85","author":"J Jiang","year":"2025","unstructured":"Jiang, J. et al. LHX2 rewires the metabolic and epigenetic landscape to drive tumor progression in prostate cancer. Cancer Res 85, 4751\u20134768 (2025).","journal-title":"Cancer Res"},{"key":"1398_CR57","doi-asserted-by":"publisher","first-page":"12315","DOI":"10.1073\/pnas.1922207117","volume":"117","author":"JJ Alumkal","year":"2020","unstructured":"Alumkal, J. J. et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc. Natl. Acad. Sci. USA 117, 12315\u201312323 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1398_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi, S. et al. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies. Proc. Natl. Acad. Sci. USA 121, e2322203121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01398-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:02:51Z","timestamp":1783900971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01398-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01398-x","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}